Vectura Group PLC (VEC) Insider Purchases £149.94 in Stock
Vectura Group PLC (LON:VEC) insider Andrew Derodra bought 153 shares of the business’s stock in a transaction on Friday, December 8th. The stock was acquired at an average cost of GBX 98 ($1.32) per share, for a total transaction of £149.94 ($201.80).
Andrew Derodra also recently made the following trade(s):
- On Wednesday, November 8th, Andrew Derodra bought 156 shares of Vectura Group stock. The stock was acquired at an average cost of GBX 96 ($1.29) per share, for a total transaction of £149.76 ($201.56).
- On Friday, October 6th, Andrew Derodra bought 142 shares of Vectura Group stock. The stock was acquired at an average cost of GBX 106 ($1.43) per share, for a total transaction of £150.52 ($202.58).
Shares of Vectura Group PLC (VEC) opened at GBX 112 ($1.51) on Friday. Vectura Group PLC has a 52-week low of GBX 86.50 ($1.16) and a 52-week high of GBX 166.97 ($2.25).
A number of equities analysts have issued reports on VEC shares. J P Morgan Chase & Co cut their target price on Vectura Group from GBX 180 ($2.42) to GBX 175 ($2.36) and set an “overweight” rating on the stock in a research report on Friday, November 10th. Numis Securities reissued a “buy” rating and set a GBX 205 ($2.76) price target on shares of Vectura Group in a research report on Thursday, September 7th. Peel Hunt reissued a “hold” rating and set a GBX 160 ($2.15) price target on shares of Vectura Group in a research report on Thursday, November 9th. Panmure Gordon reissued a “buy” rating and set a GBX 150 ($2.02) price target on shares of Vectura Group in a research report on Thursday, November 9th. Finally, Royal Bank of Canada raised Vectura Group to a “sector performer” rating and set a GBX 119 ($1.60) price target on the stock in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Vectura Group presently has a consensus rating of “Buy” and a consensus target price of GBX 177.89 ($2.39).
Vectura Group Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with Analyst Ratings Network's FREE daily email newsletter.